---

---

treatment   sector : Health care and social assistance   

save search

---

BioCorRx Pharmaceuticals Inc. Awarded NIDA Grant of Approximately $11 million Over Three Years for Research on BICX104, a Naltrexone Implant in Combination with Bupropion for the Treatment of MUD
Published: 2024-02-28 (Crawled : 16:00) - globenewswire.com
BICX | $0.75 4.2K |

Health Care and Social Assistan...

| -21.88% | O: 2.08% H: 12.24% C: 2.04%
bicx104 million treatment pharmaceuticals research grant implant

---

Biora Therapeutics Announces FDA Clearance of IND Application for Drug/Device Combination BT-600 Targeting Treatment of Ulcerative Colitis
Published: 2023-11-30 (Crawled : 00:00) - biospace.com/
BIOR | $0.6351 4.78% 280K |

Health Care and Social Assistan...

| -49.59% | O: 3.31% H: 2.4% C: -0.8%
bt-600 fda treatment clearance application therapeutics

---

Reunion Neuroscience Inc. Announces FDA Clearance of IND Application to Initiate a Phase 2 Study of RE104 for the Treatment of Postpartum Depression
Published: 2023-09-18 (Crawled : 12:00) - globenewswire.com
REUN | $1.12 -0.89% 0 |

Health Care and Social Assistan...

| Email alert Add to watchlist
re104 fda depression treatment clearance application study

---

BioCorRx Submits Expanded Access Treatment Protocol to FDA for BICX104, Implantable Biodegradable Naltrexone Pellet for Treatment of Opioid Use Disorder
Published: 2023-08-15 (Crawled : 13:00) - globenewswire.com
BICX | $0.75 4.2K |

Health Care and Social Assistan...

| -54.27% | O: 15.85% H: 0.0% C: 0.0%
bicx104 fda opioid treatment

---

BioCorRx Submits Fast Track Application to FDA for BICX104, an Implantable Biodegradable Naltrexone Pellet for The Treatment of Opioid Use Disorder
Published: 2023-07-18 (Crawled : 12:00) - globenewswire.com
BICX | $0.75 4.2K |

Health Care and Social Assistan...

| -59.68% | O: 8.6% H: 9.9% C: 9.41%
bicx104 fda opioid treatment application

---

Viridian Therapeutics Doses First Subject in First-in-Human Clinical Trial Evaluating VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Published: 2022-03-21 (Crawled : 14:20) - globenewswire.com
VRDN | $14.615 2.2% 180K |

Health Care and Social Assistan...

| -28.57% | O: 0.75% H: 6.59% C: 1.34%
vrdn-002 disease antibody treatment thyroid eye trial therapeutics

---

BioCorRx Announces Completion of Treatment Phase of Study Subjects and Preliminary Safety Data from Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2023-01-19 (Crawled : 14:20) - biospace.com/
BICX | $0.75 4.2K |

Health Care and Social Assistan...

| -39.02% | O: 3.25% H: 0.0% C: 0.0%
bicx104 treatment opioid trial study

---

BioCorRx Completes Final Subject Enrollment in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2022-10-13 (Crawled : 13:00) - biospace.com/
FNCTF | News | $11.16 130 |

Communications

| 23.59% | O: -4.1% H: 0.0% C: 0.0%
bicx104 treatment opioid trial

---

BioCorRx Announces First Subject Dosed in Phase I Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2022-06-30 (Crawled : 17:00) - biospace.com/
FNCTF | News | $11.16 130 |

Communications

| -5.93% | O: 1.06% H: 0.0% C: 0.0%
BICX | $0.75 4.2K |

Health Care and Social Assistan...

| -67.81% | O: 6.44% H: 0.81% C: 0.81%
bicx104 treatment opioid trial

---

BioCorRx Begins Recruitment for Clinical Trial of BICX104, an Implantable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2022-04-27 (Crawled : 13:20) - biospace.com/
BICX | $0.75 4.2K |

Health Care and Social Assistan...

| Email alert Add to watchlist
FNCTF | News | $11.16 130 |

Communications

| Email alert Add to watchlist
bicx104 treatment opioid trial

---

BioCorRx Announces IRB Approval to Begin Phase I Clinical Trial of BICX104, an Implantable Biodegradable Naltrexone Pellet for the Treatment of Opioid Use Disorder
Published: 2022-03-16 (Crawled : 13:30) - biospace.com/
BICX | $0.75 4.2K |

Health Care and Social Assistan...

| -79.22% | O: 0.83% H: 0.0% C: 0.0%
bicx104 treatment implant order trial approval trex one opioid

---

Ethema's ARIA Treatment Center Receives Rate Increases
Published: 2022-03-02 (Crawled : 14:30) - globenewswire.com
GRST | $0.0004 0.0% 220K |

Health Care and Social Assistan...

| -61.11% | O: 0.0% H: 11.11% C: -11.11%
treatment ema

---

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug Application to Initiate Clinical Development of VRDN-002, a Next Generation IGF-1R Antibody for the Treatment of Thyroid Eye Disease
Published: 2022-01-31 (Crawled : 15:00) - biospace.com/
VRDN | $14.615 2.2% 180K |

Health Care and Social Assistan...

| -21.99% | O: 0.55% H: 10.04% C: 9.06%
vrdn-002 new drug treatment fda clearance eye application eye disease drug therapeutics disease fda clearance antibody

---

Viridian Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for VRDN-001, an IGF-1R Antibody for the Treatment of Thyroid Eye Disease (TED)
Published: 2021-11-15 (Crawled : 12:00) - globenewswire.com
VRDN | $14.615 2.2% 180K |

Health Care and Social Assistan...

| -22.95% | O: 3.83% H: 0.0% C: -0.67%
new drug disease fda clearance treatment fda eye application eye disease antibody drug clearance

---

Viridian Therapeutics Submits Investigational New Drug Application for VRDN-001, an IGF-1R antibody for the treatment of Thyroid Eye Disease, to the U.S. Food and Drug Administration
Published: 2021-10-14 (Crawled : 12:00) - globenewswire.com
VRDN | $14.615 2.2% 180K |

Health Care and Social Assistan...

| -13.8% | O: 0.36% H: 6.46% C: -0.48%
new drug disease food treatment eye eye disease antibody drug

---

Gainers vs Losers

87%

13%

Top 10 Gainers

MTTR | News M | $4.56 162.07% 21M |

AGBA | $2.74 119.2% 52M |

Finance

CZOO | $9.07 81.76% 22M |

EDBL | News | $6.56 74.47% 1.8M |

MTC | $2.21 41.67% 5.6M |

Technology Services

OPRT | News | $3.12 38.67% 11M |

Finance

PALI | $6.59 33.67% 23M |

Manufacturing

VNRX | $0.7945 32.42% 3.1M |

Health Technology

MLEC | $1.81 29.29% 2.8M |

n/a

BTCM | $3.45 27.78% 640K |

Arts, Entertainment, and Recrea...

---

Your saved searches

---